Search Results - "O‘Brien, Mary"

Systemic therapy of advanced non-small cell lung cancer: Major-developments of the last 5-years by Cufer, Tanja, Ovcaricek, Tanja, O’Brien, Mary E.R

“…Abstract The standard palliative treatment for advanced stage NSCLC remains a platinum doublet but by tailoring chemotherapy according to tumour histology the…”
Get full text

A review of computer vision-based approaches for physical rehabilitation and assessment by Debnath, Bappaditya, O’Brien, Mary, Yamaguchi, Motonori, Behera, Ardhendu

“…The computer vision community has extensively researched the area of human motion analysis, which primarily focuses on pose estimation, activity recognition,…”
Get full text

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial by Kelly, Karen, Altorki, Nasser K, Eberhardt, Wilfried E E, O'Brien, Mary E R, Spigel, David R, Crinò, Lucio, Tsai, Chun-Ming, Kim, Joo-Hang, Cho, Eun Kyung, Hoffman, Philip C, Orlov, Sergey V, Serwatowski, Piotr, Wang, Jiuzhou, Foley, Margaret A, Horan, Julie D, Shepherd, Frances A

“…Epidermal growth factor receptor (EGFR) -tyrosine kinase inhibitors have proven efficacy in advanced non-small-cell lung cancer (NSCLC). We hypothesized that…”
Get full text

Local opinion leaders: effects on professional practice and healthcare outcomes by Flodgren, Gerd, O'Brien, Mary Ann, Parmelli, Elena, Grimshaw, Jeremy M

“…Clinical practice is not always evidence-based and, therefore, may not optimise patient outcomes. Local opinion leaders (OLs) are individuals perceived as…”
Get more information

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer by von Pawel, Joachim, Jotte, Robert, Spigel, David R, O'Brien, Mary E R, Socinski, Mark A, Mezger, Jörg, Steins, Martin, Bosquée, Léon, Bubis, Jeffrey, Nackaerts, Kristiaan, Trigo, José M, Clingan, Philip, Schütte, Wolfgang, Lorigan, Paul, Reck, Martin, Domine, Manuel, Shepherd, Frances A, Li, Shaoyi, Renschler, Markus F

“…Amrubicin, a third-generation anthracycline and potent topoisomerase II inhibitor, showed promising activity in small-cell lung cancer (SCLC) in phase II…”
Get full text

Healthcare professionals' perceptions of pulmonary rehabilitation as a management strategy for patients with chronic obstructive pulmonary disease: a critical interpretive synthesis by Swift, Emma, O'Brien, Mary R., Peters, Sarah, Kelly, Carol

“…To establish literature regarding healthcare professionals' perceptions of pulmonary rehabilitation as a management strategy for patients with chronic…”
Get full text

Factors that enable effective One Health collaborations - A scoping review of the literature by Errecaborde, Kaylee Myhre, Macy, Katelyn Wuebbolt, Pekol, Amy, Perez, Sol, O'Brien, Mary Katherine, Allen, Ian, Contadini, Francesca, Lee, Julia Yeri, Mumford, Elizabeth, Bender, Jeff B, Pelican, Katharine

“…Advocates for a One Health approach recognize that global health challenges require multidisciplinary collaborative efforts. While past publications have…”
Get full text

Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer by O'BRIEN, Mary E. R, CIULEANU, Tudor-Eliade, TSEKOV, Hristo, SHPARYK, Yaroslav, CUCEVIA, Branka, JUHASZ, Gabor, THATCHER, Nicholas, ROSS, Graham A, DANE, Graham C, CROFTS, Theresa

“…For patients with small-cell lung cancer (SCLC), further chemotherapy is routinely considered at relapse after first-line therapy. However, proof of clinical…”
Get full text

The use of digital legacies with people affected by motor neurone disease for continuing bonds: An interpretative phenomenological analysis study by Clabburn, Oliver, Knighting, Katherine, Jack, Barbara A, O’Brien, Mary R

“…Background: Motor neurone disease is a progressive neurodegenerative disease without cure. Little is known about how young people are affected when a family…”
Get full text

The engagement of young people in their own advance care planning process: A systematic narrative synthesis by Hughes, Ben, O’Brien, Mary R, Flynn, Anita, Knighting, Katherine

“…Background: An increasing number of young people are living with life-limiting conditions. Current research about advance care planning for young people…”
Get full text

Views and experiences of young people, their parents/carers and healthcare professionals of the advance care planning process: A summary of the findings from a qualitative study by Hughes, Ben, O’Brien, Mary, Flynn, Anita, Knighting, Katherine

“…Background: Advance care planning for young people is relatively new in the UK. There is a lack of understanding about the engagement of young people in their…”
Get full text

Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapy by Castagnoli, Francesca, Doran, Simon, Lunn, Jason, Minchom, Anna, O'Brien, Mary, Popat, Sanjay, Messiou, Christina, Koh, Dow-Mu

“…Introduction The spleen is a lymphoid organ and we hypothesize that clinical benefit to immunotherapy may present with an increase in splenic volume during…”
Get full text

Meeting patients’ spiritual needs during end‐of‐life care: A qualitative study of nurses’ and healthcare professionals’ perceptions of spiritual care training by O'Brien, Mary R., Kinloch, Karen, Groves, Karen E., Jack, Barbara A.

“…Aims and objectives To explore nurses’ and healthcare professionals’ perceptions of spiritual care and the impact of spiritual care training on their clinical…”
Get full text

Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data by Rossi, Antonio, Dr, Chiodini, Paolo, PhD, Sun, Jong-Mu, MD, O'Brien, Mary E R, MD, von Plessen, Christian, MD, Barata, Fernando, MD, Park, Keunchil, Prof, Popat, Sanjay, FRCP, Bergman, Bengt, MD, Parente, Barbara, MD, Gallo, Ciro, Prof, Gridelli, Cesare, MD, Perrone, Francesco, MD, Di Maio, Massimo, MD

“…Summary Background Platinum-based chemotherapy is the standard first-line treatment for patients with advanced non-small-cell lung cancer. However, the optimum…”
Get full text

Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052) by O’Brien, Mary E.R, Gaafar, Rabab M, Popat, Sanjay, Grossi, Francesco, Price, Allan, Talbot, Denis C, Cufer, Tanja, Ottensmeier, Christian, Danson, Sarah, Pallis, Athanasios, Hasan, Baktiar, Van Meerbeeck, Jan P, Baas, Paul

“…Abstract Background This was a prospective phase II study of cisplatin and bortezomib (CB) in the first line treatment of malignant pleural mesothelioma (MPM)…”
Get full text

A Randomized Clinical Trial to Dismantle Components of Cognitive Processing Therapy for Posttraumatic Stress Disorder in Female Victims of Interpersonal Violence by Resick, Patricia A, Galovski, Tara E, Uhlmansiek, Mary O'Brien, Scher, Christine D, Clum, Gretchen A, Young-Xu, Yinong

“…The purpose of this experiment was to conduct a dismantling study of cognitive processing therapy in which the full protocol was compared with its constituent…”
Get full text

Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064) by O’Brien, Mary E.R, Gaafar, Rabab, Hasan, Baktiar, Menis, Jessica, Cufer, Tanja, Popat, Sanjay, Woll, Penella J, Surmont, Veerle, Georgoulias, Vassilis, Montes, Ana, Blackhall, Fiona, Hennig, Ivo, Schmid-Bindert, Gerald, Baas, Paul

“…Abstract Background Switch maintenance is an effective strategy in the treatment of advanced Non-Small Cell Lung Cancer (NSCLC). Pazopanib is an oral,…”
Get full text

Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS -Mutant Cancers by Stewart, Adam, Coker, Elizabeth A, Pölsterl, Sebastian, Georgiou, Alexandros, Minchom, Anna R, Carreira, Suzanne, Cunningham, David, O'Brien, Mary Er, Raynaud, Florence I, de Bono, Johann S, Al-Lazikani, Bissan, Banerji, Udai

“…It is increasingly appreciated that drug response to different cancers driven by the same oncogene is different and may relate to differences in rewiring of…”
Get full text

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial by Faivre-Finn, Corinne, Prof, Snee, Michael, DM, Ashcroft, Linda, MSc, Appel, Wiebke, MD, Barlesi, Fabrice, Prof, Bhatnagar, Adityanarayan, MD, Bezjak, Andrea, MD, Cardenal, Felipe, PhD, Fournel, Pierre, Prof, Harden, Susan, DM [Oxon], Le Pechoux, Cecile, MD, McMenemin, Rhona, MSc, Mohammed, Nazia, FRCR, O'Brien, Mary, MD, Pantarotto, Jason, MD, Surmont, Veerle, Prof, Van Meerbeeck, Jan P, Prof, Woll, Penella J, Prof, Lorigan, Paul, Prof, Blackhall, Fiona, Prof

“…Summary Background Concurrent chemoradiotherapy is the standard of care in limited-stage small-cell lung cancer, but the optimal radiotherapy schedule and dose…”
Get full text

Overcoming CYP1A1/1A2 Mediated Induction of Metabolism by Escalating Erlotinib Dose in Current Smokers by HUGHES, Andrew N, O'BRIEN, Mary E. R, PRICE, Allan, PETTY, W. Jeffrey, CHICK, Jonathan B, RANKIN, Elaine, WOLL, Penella J, DUNLOP, David, NICOLSON, Marianne, BOINPALLY, Ramesh, WOLF, Julie

“…Cigarette smoking induces CYP1A1/1A2 and is hypothesized to alter erlotinib pharmacokinetics. This study aimed to determine the maximum tolerated dose (MTD) of…”
Get full text